GlassScriptPhysician profile
Koteswara Pothineni
NPI 1093903726
$10,736.45
in general payments reported to CMS, 2019-2025
25 companies · $4,524 in 2025
The $4,524 reported for 2025 was more than what 82% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,112 · 2020: $103 · 2021: $662 · 2022: $2,174 · 2023: $649 · 2024: $1,513 · 2025: $4,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,520 · Travel and Lodging: $2,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,520.38 |
| Travel and Lodging | $2,165.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,396.12 | 2021-2025 | Linq II |
| Boston Scientific Corporation | $1,698.10 | 2022-2025 | General - Therapies, Avvigo Guidance System |
| Abiomed | $1,476.56 | 2019-2024 | Impella |
| Abbott Laboratories | $863.74 | 2019-2023 | Brk |
| Pfizer INC. | $553.51 | 2019-2024 | |
| Shockwave Medical, INC | $526.04 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Aop Health US, LLC | $304.03 | 2025 | Rapiblyk |
| Novartis Pharmaceuticals Corporation | $251.95 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.35 | 2022-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $175.26 | 2019-2022 | |
| Ancora Heart, INC. | $155.04 | 2025 | Accucinch |
| Bayer Healthcare Pharmaceuticals INC. | $138.28 | 2021-2024 | |
| Medtronic Vascular, INC. | $128.68 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $125.94 | 2023-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $116.74 | 2022-2025 | Assure Wcd |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $108.36 | 2019-2025 | Repatha |
| Novo Nordisk INC | $107.58 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Cardiovascular Systems INC. | $86.49 | 2023 | Diamondback Coronary |
| Janssen Scientific Affairs, LLC | $76.17 | 2024 | Xarelto |
| Edwards Lifesciences Corporation | $67.20 | 2023 | |
| Baxter Healthcare | $40.94 | 2022-2025 | Hillrom - Carnation Ambulatory Monitor |
| Sanofi-Aventis U.S. LLC | $39.47 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $25.88 | 2020 | |
| Livanova USA, INC. | $19.30 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Koteswara Pothineni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.